Article and Video CATEGORIES
Clinical Trials of Immune Checkpoint Inhibitors as First Line Therapy for Advanced NSCLC
Dr. Jack West summarizes the rationale for testing immune checkpoint inhibitors as a first line treatment for patients with advanced NSCLC and highlights details of two trials testing this question.
November is Lung Cancer Awareness Month. What are you grateful for?
Watch, read, and then share your own stories of empowerment in our online forum. Your story may inspire others.
[powerpress]
Get more information about the IMpower-110 Trial and CheckMate-227 Trial.
[ratingwidget post_id=0]
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Article
The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.
Image
Article
Da click aquí para más información y para registrarte ahora
Forum Discussions
Hello Janine,
Thank you for sharing this valuable leukemia playlist—building a reliable knowledge base like this truly makes a difference for everyone navigating such a challenging journey. I appreciate the open...
Recent Comments
Hi Hopish hope, Welcome to…
By JanineT GRACE … on